Selank

What it is

Selank is the seven-amino-acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro; FDA also lists TP-7. The form still matters: the substance record maps Selank diacetate, while FDA's compounding page says Selank acetate (TP-7).

Those records support identity and search-language mapping. They do not show that Selank, Selank acetate, Selank diacetate, and TP-7 are interchangeable finished products.

Why people care

Selank is commonly discussed as an anxiety or “nootropic” peptide. The human record is not empty, but it is easy to overstate: the identified anxiety papers are small, rely heavily on English abstracts from Russian-language publications, and do not provide the modern placebo-controlled evidence or complete adverse-event reporting implied by a broad “clinically proven” claim.

What humans actually show

• 2008 active-comparator study: PubMed indexes the Russian-language paper as a randomized controlled trial. Its English abstract describes 62 patients with generalized anxiety disorder or neurasthenia: 30 received Selank and 32 received medazepam. It reports similar anxiolytic effects on psychometric measures. This was an active-comparator study, not placebo-controlled; route and allocation details are incomplete in the English abstract, and the record cannot establish equivalence or long-term safety.
• 2014 phenazepam comparison: The English abstract describes 60 patients with phobic-anxiety and somatoform disorders and reports anxiolytic, mild “nootropic,” quality-of-life, and tolerability findings. No placebo arm is described, and allocation, masking, route, duration, outcome completeness, and adverse-event details could not be adequately assessed from the abstract.
• 2015 adjunctive study: Thirty patients received phenazepam alone and 40 received Selank plus phenazepam. The abstract reports earlier improvement on one scale and fewer phenazepam-associated undesirable effects in the combination group. This does not isolate a pharmacokinetic interaction or establish that Selank generally prevents benzodiazepine adverse effects.
• 2020 functional-connectivity study: A study of 52 healthy participants reported resting-state connectivity changes after Selank, Semax, or placebo involving the right amygdala and right temporal cortex. Imaging changes are biomarkers, not clinical anxiety or cognition outcomes.

Mechanistic and nonhuman evidence

A 2001 paper examined enkephalin-degrading activity in people with anxiety disorders and tested Selank’s inhibition of enzymatic hydrolysis in human plasma. A 2008 paper reported cytokine findings in patients and ex-vivo blood-cell work. These records may help generate hypotheses; enzyme, cytokine, or connectivity changes do not establish clinical efficacy.

FDA and U.S. status

FDA’s compounding-safety page places Selank acetate (TP-7) among bulk-drug nominations withdrawn by nominators. FDA says compounded Selank acetate may pose immunogenicity risk for certain routes because of possible aggregation and peptide-related impurities, and that important information about safety issues raised by human administration is lacking.

A 2020 FDA warning letter named Selank among substances used by one inspected compounder. The letter’s findings are firm- and inspection-specific. Exact Drugs@FDA searches for Selank and Selank acetate returned no matches on July 27, 2026, but PepCurrent does not convert an empty database result into an FDA approval, nonapproval, legality, or product-specific conclusion.

Risks and warning limits

PepCurrent located no FDA-approved Selank prescribing information. The small abstracts do not provide a complete adverse-event profile. FDA identifies possible immunogenicity, aggregation, and peptide-impurity concerns for compounded Selank acetate and says important human safety information is lacking. Limited adverse-event reporting cannot be interpreted as evidence of safety.

What remains unknown

• Whether Selank improves anxiety versus placebo in an adequately powered, well-reported modern trial.
• Whether any cognitive outcome is clinically meaningful and independently replicated.
• Long-term adverse effects, contraindications, interaction profile, and route-specific safety.
• Whether the cited study products have the same identity as any other formulation or product.

Product identity and quality limits

A paper about a defined study product does not verify an unrelated vial. Sequence or alias alone cannot establish the salt form, formulation, concentration, purity, sterility, aggregation state, stability, or storage history of a product labeled Selank, Selank acetate, Selank diacetate, or TP-7.

What has been studied together

The 2015 study is direct but narrow coadministration evidence for Selank plus phenazepam in the studied population. It is not a pharmacokinetic interaction study and cannot establish class-wide compatibility, safety with other medicines or peptides, or a personalized combination recommendation. No broader direct interaction program was identified in the July 27 searches.

What people are hearing

• “Selank is a proven anxiety treatment.” The identified human studies include active-comparator and adjunctive evidence, not a well-reported modern placebo-controlled program.
• “Nootropic means it improves cognition generally.” One comparative patient-study abstract uses the phrase “mild nootropic,” while the imaging study reports functional-connectivity changes. Neither establishes a general cognitive benefit.
• “A product with the same name is the studied product.” The name does not establish salt form, formulation, concentration, purity, sterility, stability, or storage history.

Questions readers raise

Readers ask whether Selank “works like” an approved anxiety medicine, whether imaging changes prove a nootropic effect, and whether products sharing the name reproduce the studies. These are questions to investigate, not evidence of benefit or safety. PepCurrent has not published anecdotal theme counts or public user reviews for this profile.

What would change this answer

• A well-reported, adequately powered placebo-controlled trial with a defined Selank product and patient-important outcomes.
• Complete methods and adverse-event reporting from the existing human studies.
• Replicated clinical cognition outcomes rather than imaging or mechanistic markers alone.
• Official product-specific FDA action or labeling for an exact Selank product.
• Direct interaction evidence for a defined product and coadministered medicine.

Sources and records

• FDA compounding-safety record
• FDA GSRS substance record for Selank
• FDA Tailor Made Compounding warning letter
• 2008 active-comparator study — PMID 18454096
• 2014 phenazepam-comparator study — PMID 25176261
• 2015 adjunctive study — PMID 26356395
• 2020 functional-connectivity study — PMID 32342318
• 2001 enkephalin-mechanism paper — PMID 11550013
• 2008 immunologic paper — PMID 18577961
• Reproducible PubMed search